26
Why low-cost ketamine is still inaccessible to many with severe depression | The George Institute for Global Health
(www.georgeinstitute.org.au)
this post was submitted on 25 Oct 2023
26 points (93.3% liked)
Everything Science
420 readers
4 users here now
it is the place for high quality scientific content that doesn't necessarily reference a peer-reviewed paper from the last 6 months.
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
I mean, just with basic knowledge of healthcare and pharmaceuticals in the US you can deduce that low cost treatments like ketamine aren't available because they can't produce the same level of profit as a freshly patented new drug. US wealthcare isn't interested in low cost treatments that work quickly with a minimum number of interventions, the entire system is setup to keep patients on maintenance doses of maximally profitable drugs as long as possible.